 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
|
|
|
Phase II, Phase I
|
|
|
|
CCC-PHII-75
7435, NCI-7435, NCT00365157
|
|
| |
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
|
|
|
|
Phase II
|
|
|
|
MDA-ID-030111
NCT00082706
|
|
| |
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
|
|
|
|
Phase II
|
|
|
|
MSKCC-06081
NCT00397488
|
|
| |
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
|
|
|
|
Phase II
|
|
|
|
UMCC 2005.145
NCT00393796
|
|
| |
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
|
|
|
|
Phase II
|
|
|
|
MCCRC-MC0553
7661, MC0553, NCT00471536
|
|
| |
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma
|
|
|
|
Phase II
|
|
|
|
0609001823
NCT00461851
|
|
| |
Gemcitabine, Paclitaxel, Doxorubicin, and Pegfilgrastim in Treating Patients With Metastatic or Unresectable Bladder Cancer or Urinary Tract Cancer and Kidney Dysfunction
|
|
|
|
Phase II
|
|
|
|
MDA-2005-0839
MDA-2005-0939, 2005-0839, 7341, NCT00478361
|
|
| |
Randomized Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
|
|
|
|
Phase II
|
|
|
|
UMCC 2007.097
NCT00645593
|
|
| |
A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer
|
|
|
|
Phase II
|
|
|
|
D2782C00010
NCT00661609
|
|
| |
Gemcitabine and Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
|
|
|
|
Phase II
|
|
|
|
07-168
NCT00714948
|
|
